Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins
Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.
Product Name : Tears Naturale Forte
Product Type : Carbohydrate
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : LMW-Dextran Sulfate,Dextrans
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles.
Product Name : ILB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2022
Lead Product(s) : LMW-Dextran Sulfate,Dextrans
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : These studies show that ILB® releases, re-distributes and modulates the bioactivity of endogeneous heparin-binding growth factors that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effec...
Product Name : ILB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 31, 2022
Details : The collaboration will support TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential and clinical development, regulatory and commercial strategies.
Product Name : ILB
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : LMW-Dextran Sulfate,Dextrans
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tikomed's ILB® Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat
Details : The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.
Product Name : ILB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : LMW-Dextran Sulfate,Dextrans
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)
Details : ILB (Dextran Sulfate) is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : ILB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2018
Details : ILB (Dextran Sulfate) is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : ILB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2018
Lead Product(s) : Dextrans
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : Defence Research and Development Canada
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dextran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Brain Injuries, Traumatic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 17, 2012
Lead Product(s) : Dextrans
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : Defence Research and Development Canada
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
